#1doximity INVESTOR DAY 2023 June 6, 2023 MOTORL HOSPITAL#2SAFE HARBOR This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial and operating metrics, capital expenditures, plans for future operations, competitive position, technological capabilities, and strategic relationships, general business conditions and the assumptions underlying those statements. Any forward-looking statements contained in this presentation and associated commentary are based upon Doximity's historical performance and its plans, estimates and expectations as of the dates noted in this presentation, and are not a representation that such plans, estimates, or expectations have been or will be achieved. These forward- looking statements represent Doximity's expectations as of the dates noted in this presentation. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Subsequent events may cause these expectations to change, and Doximity disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including, but not limited to, those related to our business and financial performance, our ability to attract and retain customers, our ability to develop new products and services and enhance existing products and services, our ability to respond rapidly to emerging technology trends, our ability to execute on our business strategy, our ability to compete effectively and our ability to manage growth. Additional risks and uncertainties that could affect Doximity's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's filings with the Securities and Exchange Commission on Form 10-K and subsequent Form 10-Qs. These materials are available on our investor relations website at investors.doximity.com under the Financials section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Doximity makes with the SEC from time to time. In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and associated commentary may include certain non-GAAP financial measures (including on a forward-looking basis). Definitions and reconciliations of non-GAAP measures to their most directly comparable GAAP counterparts are available in our most recent Form 10-K or 10-Q on the company's investor relations website at investors.doximity.com. doximity DOCS Investor Day - June 6, 2023#3AGENDA Tuesday, June 6; 10:30AM - 12:30PM ET Topic Intro Product Demo Physician Panel 10 min Break Commercial Products Commercial Ops Financials Q&A doximity Speaker(s) Jeff Tangney | Co-Founder & CEO Nate Gross, MD | Co-Founder & CSO Moderator: Chris Longhurst, MD | CMO & CDO UCSD Ben Greenberg | SVP Commercial Products Craig Overpeck | SVP Commercial Ops Anna Bryson | CFO Jeff Tangney | Nate Gross, MD | Anna Bryson DOCS Investor Day - June 6, 2023#4KICKOFF doximity 45000k Jeff Tangney CEO & Co-Founder DOCS Investor Day - June 6, 2023#5THE PHYSICIAN CLOUD Network o News Phone/ Fax Schedule Mission: help doctors be more productive 80%+ 20/20 of U.S. Physicians and 50%+ NP/PAS¹ Top Hospitals and Pharma² $419m FY23 Revenue Telehealth 1. As of 3/31/23. 2. Top 20 Pharmaceutical Manufacturers based on data from FiercePharma, Top 20 hospitals based on U.S. News & World Report's Best Hospitals 2021-2022 Rankings as of 3/31/23. 3. See appendix for the definition and a reconciliation of this measure to its nearest GAAP equivalent. doximity $184m FY23 Adj EBITDA³ Values: Physicians First, Docs-'n-Dorks, GSD Founded: 2010 Employees': 977 DOCS Investor Day June 6, 2023#6FIVE YEARS OF GROWTH & PROFIT $300m $200m $100m $0m doximity $86 $10 FY19 $116 $27 FY20 $207 $65 FY21 $344 $150 FY22 $419 $184 FY23 $503 $219 FY24E Revenue ($m) Adj. EBITDA¹ ($m) - 10X+ median ROI - 124% NRR with Top 20 clients' - 44% Adj EBITDA 1. See appendix for the definition and a reconciliation of this measure to its nearest GAAP equivalent. 2. See appendix for the definition of this metric. DOCS Investor Day - June 6, 2023#7In Millions WHAT'S CHANGED SINCE IPO Revenue up 2.0x Adj EBITDA¹ up 2.8x $400 $300 $200 $100 $0 FY21 FY23 In Millions $400 $300 $200 $100 1. See appendix for the definition and a reconciliation of this measure to its nearest GAAP equivalent. 2. Represents % of all U.S. MDs and DOs covered by paid Doximity enterprise subscriptions. As of 3/31. doximity $0 FY21 FY23 % of All US Physicians Enterprise Subs up 1.7x² 40% 30% 20% 10% 0% Telehealth FY21 FY23 Schedule Cross-sell (both) DOCS Investor Day - June 6, 2023#8WORKFLOW IS OUR SECOND ACT Quarterly Active Telehealth Providers¹ 300k 200k 100k Ok Jun-19 Sep-19 Dec-19 doximity Mar-20 Jun-20 Dec-20 Sep-20 Mar-21 Jun-21 Dec-21 Sep-21 Jun-22 Mar-22 Sep-22 Dec-22 Mar-23 BEST IN KLASⓇ VIDEO CONFERENCING PLATFORMS 2022 BEST IN KLAS VIDEO CONFERENCING PLATFORMS 2023 - 86% "part of long-term plan"² - 96% renewal rate³ - Cross-sell motion: MedStar Health 1. Virtual visits conducted by MD, DO, NP, PA credentials greater than 2 minutes in length 2. KLAS survey data, February 2023 3. Based on # of MD/DO/NP/PA under enterprise subscriptions retained in FY23 4.% of MD/DOs covered by both paid Dialer and Amion subscription licenses DOCS Investor Day June 6, 2023#9GLARING DAY-TO-DAY INEFFICIENCIES doximity 80% of U.S. HC documents still sent via snail mail and fax¹ 78% of physicians report health IT related burnout² 73% of $4.3 trillion/yr in US HC is decided by doctors³ 1. Keeping it Together Issue Brief on Exchanging Medical Documentation CAQH Nov 2020. Does not include email. 2. 2018 Survey of America's Physicians Practice Patterns and Perspectives, The Physicians Foundation by Merritt Hawkins, September 2018 3. Center for Medicare & Medicaid Services, including categories of hospital care, physician and clinical services, retail prescription drugs, nursing care facilities & continuing care retirement communities, home health care, and durable medical equipment.#10'CUT THE SCUT' WITH AI Half of physician time today is spent on admin work. Al can save 13hr/wk, reducing average doc to 50hr/wk¹. DOXIMITY AI LABS DocsGPT.com - 000's doc prompts per week - Built-in fax to insurers - Psych & PCP biggest users - Adding to our post-call flow 1. From June 2023 Doximity survey of 322 physicians who've used DocsGPT and other Al technologies. doximity 0° BestDoc.ai (new) - Builds on hospital Referral/Appt biz - Just enter a diagnosis & bot helps navigate to right sub-specialists DOCS Investor Day - June 6, 2023#11WHAT HASN'T CHANGED SINCE IPO doximity PHYSICIANS FIRST doxia JBAR WEEKEND SUMMITS 907 FOUNDER-LED MISSION-DRIVEN TEAM 2011 2021 www DOCS N' DORKS GSD DOCS for Doc mel wew DOCS B DOCS Investor Day June 6, 2023#12PRODUCT doximity Nate Gross, MD CSO & Co-Founder DOCS Investor Day - June 6, 2023#13PURPOSE BUILT FOR MEDICINE Professional Network 9:41 Fatima Cody Stanford, MD MPH, MPA, FAAP, FACP, FAHA, FTOS Medicine/Pediatrics. Boston, MA Add Colleague Obesity Medicine & Nutrition Physician- Massachusetts General Hospital; Instructor of Medicine and Pediatrics-Harvard Medical School 150+ Colleagues doximity.com Contact Info MGH Weight Center 50 Staniford St, 4th Floor Boston, MA 02114 PHONE (588) 764-0021 all FAX (558) 246-9753 1000090713 doximity Send Message View All Clinical Expertise Health promotion, Health status disparities, Obesity and related-dieerdere Weight loss (1) 9:41 doximity.com Work Experience Harvard Medical School - Boston, MA Obesity Medicine & Nutrition Clinical & Research Fellow January 2012 - Present Mass General Hospital Boston, MA Obesity Medicine and Nutrition Attending Physician Education & Training Massachusetts General Hospital Fellowship, Obesity Medicine & Nutrition, 2012-2015 Palmetto Richland Memorial Hospital Residency, Internal Medicine/Pediatrics, 2008-2012 Medical College of Georgia School of Medicine. Fellowship, Dean's Summer Research, 2004-2004 9 more Certification & Licensure MA State Medical License. 2013-2022 American Board of Pediatrics Pediatrics Newsfeed 9:41 Your classmate Paul Smith commented MedRxiv 1d d A Novel Variant of Interest of SARS-CoV-2 with Multiple Spike Mutations is Identified from Travel Surveillance in Africa 7min read Exploring the Network Paul Smith, MD Internal Medicine News Geonomics 17 33 Comments ☎ Key Points: This variant of interest (VOI) has 31 amino acid substitutions and ...more ↑ Vote + Reply Add a comment Q C 12 Search Dialer Fax/Msg ...more Careers Workflow < 9:41 500 Main Street San Francisco CA TAL, MO Anita Patel, MD from 41 Subject Patient test results Please see patient test results Reply F: 555-555-5555 Date: 5/2/2002 Page 1 Chand Forward ? Edit ¹ FO 9:41 4 visit.doximity.com Dr. Cheryl Chavez Endocrinology Stop Mute Flip û .... -- M Photo Ĉ SENTARA 0 DOCS Investor Day - June 6, 2023#14H ADOPTION >500,000 Quarterly Active Workflow Providers¹ Secure Email Telehealth elle Fax & e-Signature Schedule 9:41 Close SUN MON THU, MAR 7 Leave AZ1 6 7 8 13 14 15 20 21 22 27 28 29 MON, MAR 8 Day Attending Mercy Hospital TUE, MAR 9 TUE 1 OV Clinic Mercy Hospital WED, MAR 15 Lu, Cathy PGY2 March 2021 WED THU 2 9 16 17 23 24 30 31 32 10 FRI 4 SAT 01 5 11 12 18 19 25 26 7a-7a Leave 5p-7a MICU 1 7a-6p OV Clinic esc O § + 1 FI Q 393 17 2 A F2 W S 20 1. Quarterly Active Workflow Providers counts all unique MDS, DOS, NPS, PAS, CRNAS, Med Students, and Pharmacists who used at least one productivity tool (telehealth, scheduling, digital fax and e-signature, and DocsGPT). As of March 31, 2023. 2. As of March 31, 2023. doximity 3 E € Ç 4 R 4.8 out of 5, 150K+ Ratings & Reviews² "This app has changed my professional life." 5 F T DOCS Investor Day June 6, 2023 & 6 N B#15CHRIS LONGHURST, MD per Longhun, MD Ley 201 HD DOXIE AWARD WINNERS DOCS Investor Day - June 6, 2023#16James DuRant, MD Medical Director Novant Health Center for Pediatric Development EHR Picture-in-a-Picture doximity Chrome File Edit View MyChart Administration SMITH, GLORIA - 12247 Billing Demographics Immunization History" Referrals Prescriptions" Message History* Comments Injections" Growth Charts Letters Flowsheet" PFSH Patient Summary" Outside Procedures* eOffice Notes* PFSH Patient Education" Obstetrics Forms" Patient Portal" Outside Diagnostics" Appointments* Chronic Care" Medication Admin Implantable Devices" Imported Encounters History Bookmarks People Tab Window D Maintenance interface Monitor Sche MISCELLANEOUS PROBLEM LIST DATE NAME 04/09/19 CHRONIC FRONTAL SINUSITIS 04/09/19 CHRONIC LARYNGITIS DATE No records to display. SMITH, GLORIA L FEMALE DOB: 7/21/1985 (33 YEARS, 8 MONTHS) PHY: SMITH, DAVID PRI: SEC: DESCRIPTION ALLERGIES DATE 10/15/18 Replying to @Toshia_Shaw You can pop the video screen out which I love bc it makes charting during video sessions easy. Josh 6:56 PM Jan 5, 2023 56 Views @Life_W_Josh NAME (REACTION) peanut ((Urticaria NOS) or (hives)) OFFICE NOTES DATE SUBJECT 03/25/19 OV-Pain of right foot 02/20/30 OK ACUTE LARYNGITIS Problem History + PENDING ORDERS/REMINDERS STATUS Active Active DUE DATE NAME No records to display. + CURRENT MEDICATIONS DATE MacBook Pro Allergy History + LABS/DIAGNOSTICS STATUS Active NAME (HOW TAKEN) Advil 100 mg chewable tablet (PO 03/26/19 TID) 10/15/18 Singulair 10 mg tablet (1 a day) 03/26/19 Tylenol 325 mg capsule (BID PO) DATE 02/20/19 A1C PROCEDURE NAME LAST SEEN: 03/25/2019 Med History Office Notes (Filter by Diagnosis) RECENT UPLOADED IMAGES/DOCUMENTS PROVIDER DATE D Smith No records to display. D. Seith DOCUMENT TYPE NK Meds STATUS Active Active Active DOCS Investor Day June 6, 2023#17Fatima Stanford, MD Obesity Medicine Harvard Medical School & Mass General Conference Connect doximity Dear Dr. Stanford, We compiled a list of people you might know going to ASH. Click below to send them a note to meet up. See all attendees CONFERENCE ATTENDEES Katherine High, MD Pediatric Hematology & Oncology Professor, Pediatrics, Perelman School of Medicine Classmate from Harvard Joseph Alvarnas, MD Oncology Director of Value-Based Analytics Senior Medical Director Speaking at ASH 2018 Terry Gernsheimer, MD Hematology Professor, Medicine, University of Washington School of Medicine Co-Resident from Beth Israel Deaconess Medical Center Internal Medicine Program Catherine Coombs, MD Hematology Assistant Professor ASH Attendee Send note Send note View View#18Tommy Korn, MD Ophthalmologist & CDIO Sharp Healthcare Calendly doximity Doximity Integrates with Calendly to Automate Physician Meeting Scheduling A virtual personal scheduling assistant for busy doctors Doximity today announced a first-of-its-kind app alliance to streamline how doctors arrange their clinical and life science meetings with an integration with Calendly. Each year, doctors attend millions of educational events to stay up-to-date on the latest treatments. Scheduling these meetings can often be time-consuming and tedious with lots of emails and texts back-and-forth. Impromptu visits, meanwhile, can disrupt clinical workflows and are not efficient to any party. By providing each doctor with access to Calendly's scheduling automation capabilities within the Doximity platform, we hope to save physicians' time so they can focus on what matters most - providing the best care for their patients. C Calendly DOCS Investor Day June 6, 2023#19well-wre Lea Ann Chen, MD Gastroenterology, Rutgers Robert Wood Johnson Medical School DocsGPT Letters of Recommendation doximity Prompt Library Trending Rituxan Denial Appeal https://www.doximity.com/docs-gpt Mounjaro Denial Appeal Letter of Medical Necessity SOAP Note BPH Patient Handout Letter of Rec for Resident Clinical Correspondence ▾ Charting Patient Education ▾ Miscellaneous ▼ > > > > Write a letter of recommendation for an internal medicine resident applying for endocrinology. She is smart, passionate, and active, and has presented abstracts at national meetings. PLEASE EDIT FOR ACCURACY B DocsGPT BETA Generating... Write a letter of recommendation for an internal medicine resident applying for endocrinology. She is smart, passionate, and active, and has presented abstracts at national meetings. Give it a Try DOCS Investor Day - June 6, 2023#20Chris Longhurst, MD CMO & CDO UC San Diego Health US News Voting doximity Chrome File Edt Vine History Bookmarin People Tab Window D done (De X + [email protected] "doximity The Medical Network Where care comes together First Name Last Name Aiready on Doximity? Sign in APP Dialer Video DIALER PARTNERS Find My Profile Dialer Voice Search U.S. News Best Hospitals Nominate up to 5 hospitals for the U.S. News Best Hospitals. Submit your Nominations Sing These Who ar 000 S BEST HOSPITALS us.News RANKINGS CME DOCS Investor Day - June 6, 2023#21PHYSICIAN PANEL doximity Moderated by: Chris Longhurst, MD Chief Medical Officer & Chief Digital Officer UC San Diego Health DOCS Investor Day - June 6, 2023#2210-MINUTE BREAK doximity DOCS Investor Day - June 6, 2023#23COMMERCIAL PRODUCTS doximity Ben Greenberg SVP Commercial Products DOCS Investor Day - June 6, 2023#24PHYSICIANS' FAVORITE APP Jason Kovac @dockovac I use @doximity every day. Send text messages and do video calls. Probably the most valuable app I have. Anabella Stark, M.D. @anaisabelstark Just want to give a shout-out to @doximity for their service! Being able to contact patients at anytime without sacrificing personal number is awesome! And an added bonus, excellent newsfeed John G. Roubil, MD @JohnRoubil Sending faxes through my cell phone, and calling patients without disclosing my personal number (comes up as my hospital's number) with the @doximity app is so simple, yet so incredibly helpful! Niyi Soetan, MD @Medical_Niyi The Doximity dialer and fax is so clutch omg doximity AppStore NPS calculated on reviews from April 2021 to April 2023. NPS = 5 star minus 1-3 star. AppStore Net Promoter Score (NPS)¹ d Drug Reference App Clinical Reference App Medical News App EHR App -100 -88 -52 -67 -50 0 6 45 50 100 DOCS Investor Day - June 6, 2023#25CORE MODULE PORTFOLIO We create customized packages for customers doximity 9:41 < Sponsored by PharmaCo Take a Closer Look at New Phase 3 Data for Doxlera® (doxilimubab) Sponsored The once daily inhalation mist of Doxlera® showed significant reduction in COPD exacerbations (flare ups). In a 24-week study, patients living with chronic obstructive pulmonary disease COPD went through a program with Doxlera® (doxilimumab) and showed significant results. Doxlera inhalation mist helps maintain the daily management and treatment of airflow obstruction in patients living with COPD. all? Significant Reduction in Rate of COPD Exacerbations with Doxlera® Annual Rate of COPD Exacerbations News O Search Dialer Fax/Mog PI Long Form 91 Cangers 9:41 0:22 Doxleraumati 7 Doxlera (doxilimubab) 6 colleagues viewed Once-weekly DOXLERA significantly improved moderate-to-severe COPD exacerbation rates with a demonstrated safety profile. 4 Add a comment wp O Learn More About Doxlera (doxilimumab) and its Mechanism of Action News As opposed to other treatments in its field, Doxlera® is unique in the fact that it can help its patients take control of their health ...more 5 INDICATION AND IMPORTANT SAFETY INFORMATION Doxiera (daxilimumab) is indicated as an adjunct to standard treatment for chronic obstructive pulmonary disease (COPD) The Washington Post 2d Q Search Med Guide all C Dialer Sponsored 23% REDUCTION Fax/Mag Video Prescribing Info Careers 9:41 a G Doxlera® (doxilimubab) 6 colleagues read 4 6.0 Add a comment 16 ₁ Discover How Doxlera Is Changing the Way Physicians Approach Medicine Doxiera works differently than most medicines in its field by directly encapsulating, binding, and inactivating abnormal Ω INDICATION AND IMPORTANT SAFETY INFORMATION Doxiera (doxilimumab) is indicated as an adjunct to standard treatment for chronic obstructive pulmonary disease (COPD) Ca News The Guardian 2d Search all? Med Guide C 19 Dialer Sponsored Fax/Msg JD Prescribing Info Short Form Careers DOCS Investor Day - June 6, 2023#26NEW VERTICAL VIDEO OFFERINGS doximity 9:41 Sponsored by Doxlera SUPERIOR relative risk reduction in 3-month CDP vs place 39% relative risk reduction with DOXANTIN (db(n-1051) vs placebo (n-10677 Waiting for Patient to Join ann, Elbasanded by a of c 0:13 View Important Safety Information below, including Bloed Warning Important Safety Information Doxlera (doxaterol) injection is indicated as an adjunct to standard treatment of cardiovascular (CV) risk factors. Read the Patient Information Leaflet if available from your pharmacist before you start taking apremilast and each time you Med Guide Prescribing Info (415) 555-4567 + add people mute stop 1:10 end Point of Care < 4:40 Today: Peter Alperin, MD > Messages are HIPAA compliant Peter Alperin, MD Sponsored by Doxlera Dear Dr. [LastName]: It's great to connect with you on Doximity. I recently presented on treatment options for patients with a history of hypersensitivity to doxaterol or nosazone. Here's a summary of my presentation. Sincerely, Peter Alperin, MD Internal Medicine - Austin, TX Assistant Professor, UT Dell Medical School Doximity, Inc. 12/23 JOB CODE Please do not reply to this message. Replies to this message are routed to an unmonitored mailbox. Add Colleague Peer to Peer 4:40 PM DOCS Investor Day June 6, 2023#27PROOF POINT: INSURANCE COVERAGE INFO AT POINT OF CARE Helps Prescribers and Our Customers - Over 80% of physicians say insurance coverage and patient cost are key prescribing factors Personalized with MD-specific payor data Helps Our Business - Leads to impactful programs with proven results - Helps break into new Life Sciences budgets - Simple sale with quick time-to-market doximity 9:41 96% PLAN-CHANNEL A Sponsored by Doxlera United Healthcare COMMERCIAL of your patients have Preferred Coverage for Doxlera® Caremark Administered.... COMMERCIAL Blue Cross California COMMERCIAL Waiting for Patient to Join AARP Medicare Rx COMMERCIAL Med Guide STATUS Tier 3 Tier 2 Tier 3 Tier 3 CO-PAY $20-$30 $22-$35 $20-$30 $22-$35 $20-$30 $22-$35 $20-$30 $22-$35 INDICATION Doxlera (doxaterol) is indicated for patients with cardiovascular disease IMPORTANT SAFETY INFORMATION Doxlera® (doxaterol) injection is indicated as an adjunct to standard treatment of cardiovascular (CV risk factors. Read the Patient Information Leaflet if available from your physician Prescribing Info#28DOCS Investor Day - June 6, 2023 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 இ இ இ 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 Calls Sponsored ~1 in 100 Point of Care Pilo Plilo ploi doximity Ollo pllo Plilo pilo pilo plilo pilo ~1 in 12 Cards Sponsored Newsfeed AD LOAD IS LOW, AD CONTENT IS CLINICAL#29COOKIES ARE CRUMBLING - (2015) Apple Safari Plugins (ad blockers) - (2017) Apple Intelligent Tracking Prevention ITP (cookies) - (2020) Safari 3rd-party cookie Blocking by default (cookies) - (2020) Apple breaks CNAME Cloaking (3P tracker subdomain) - (2021) App Tracking Transparency enforcement (IDFA) - (2021) Mail Privacy Protection (email pixels & IP address) - (2021) iCloud Private Relay (web IP address) - (2024) Chrome 3rd party cookies phase out (cookies) doximity 9:41 <iCloud Private Relay iCloud Private Relay keeps your internet activity private Private Relay hides your IP address and browsing activity in Safari and protects your unencrypted internet traffic so that no one-including Apple-can see both who you are and what sites you're visiting. IP Address Location Private Relay (Beta) Private Relay is currently in beta. Some websites may have issues, like showing content for the wrong region or requiring extra steps to sign in. Learn more...#30ANALYSIS OF 150+ BRAND CLIENTS MUCH ROOM TO GROW 2022 Breakdown of Rx Digital HCP Budgets¹ 71% Impacted by Cookie Crush Other Programmatic Email 1. Based on analysis of vendor invoicing data from pharmaceutical companies in 2022 and Doximity estimates. doximity Display Doximity Share of Rx Digital HCP Mktg¹ 20% 15% 10% 5% 0% 2019 We've gained 12% share over the last 5 years 2020 2021 2022 2023 Jan-Feb DOCS Investor Day - June 6, 2023#31COMMERCIAL OPERATIONS doximity Craig Overpeck SVP Operations DOCS Investor Day - June 6, 2023#32REP ACCESS TO U.S. PHYSICIANS IN DECLINE The number of "no see" U.S. Physicians continues to decline after a small rebound post-COVID 1. ZS Associates AccessMonitor doximity % of U.S. Doctors 100% 75% 50% 25% 0% 2008 Pharma Rep Access to U.S. Physicians¹ 2010 2012 2014 2016 2018 Includes Video Calls 2020 2022 DOCS Investor Day - June 6, 2023#33WHILE DOXIMITY DIGITAL ACCESS INCREASES >80% of all U.S. Physicians reachable on Doximity's platform 1. ZS Associates AccessMonitor doximity 100% 75% 50% 25% 0% 2008 Pharma Rep Access¹ vs. Doximity Growth 2010 2012 2014 % of U.S. Physicians Registered on DOCS 2018 Accessible U.S. Physicians 2016 2020 2022 DOCS Investor Day June 6, 2023#34JAPAN DIGITAL HCP PLATFORMS A DECADE AHEAD N M3, Inc. Founded 2000 ~325K Docs in Japan¹ doximity doximity Founded 2010 ~1M Docs in the U.S.² 1. Ministry of Health, Labor and Welfare of Japan. As of 2021. 2. Federation of State Medical Boards physician census 2020. 3. M3 revenue based on medical platform revenue. Avg. JPY/USD exchange rate from April 2022-March 2023. qu ~$2,100 Rev/Doc (M3 FY23³) d ~$400 Rev/Doc (DOCS FY23) DOCS Investor Day - June 6, 2023#35ADJACENT OPPORTUNITIES doximity 33 Peer-to-Peer 800 Clinical Trials F08 Point-of-Care Reimbursement Support MSL/Education Meetings 19 Credentialing DOCS Investor Day - June 6, 2023#36FOCUSED GTM STRATEGY $ ୭୩ TO1 doximity Manufacturers Pharma (Large, Medium, Small) Medical Devices and Diagnostics Hospitals Hospital Marketing Hospital Workflow Hospital Staffing DOCS Investor Day - June 6, 2023#37FINANCIALS doximity Anna Bryson CFO DOCS Investor Day - June 6, 2023#38FINANCIAL HIGHLIGHTS 1 Significant $18B+ market opportunity in a digitally underindexed industry 2 Substantial room to grow within existing customers 3 4 Proven profitability with 40% + adjusted EBITDA margins¹ Large and growing $840M+ cash balance² 1. For FY22 and FY23. See appendix for the definition and a reconciliation of this measure to its nearest GAAP equivalent. 2. Represents cash, cash equivalents, and marketable securities as of March 31, 2023. doximity DOCS Investor Day - June 6, 2023#39RX MARKET SIZING Note: Each box represents one brand with $100M+ in U.S. sales Estimated Doximity Share of HCP Marketing Budgets¹ 1. As of March 31, 2019. Based on data from Evaluate Pharma and Doximity estimates. doximity 1000000000 000000 100000 10000 >50% Year FY19 100000000 1000000 20-50% 5-20% <5% 00000000 ☐☐☐☐☐☐☐☐☐☐☐000 No Revenue in Trailing 12 Months #Mega Brands ~300 Doximity Share ~1% DOCS Investor Day June 6, 2023#40RX MARKET SIZING Note: Each box represents one brand with $100M+ in U.S. sales Estimated Doximity Share of HCP Marketing Budgets¹ 1. As of March 31, 2021. Based on data from Evaluate Pharma and Doximity estimates. doximity >50% 20-50% Year FY21 ☐☐☐☐☐☐☐☐☐ 10000 000000000 0000000 5-20% <5% # Mega Brands ~350 ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐ 1000000000 000000 0000000 000000 No Revenue in Trailing 12 Months Doximity Share ~2% DOCS Investor Day June 6, 2023#41RX MARKET SIZING Note: Each box represents one brand with $100M+ in U.S. sales Estimated Doximity Share of HCP Marketing Budgets¹ 1. As of March 31, 2023. Based on data from Evaluate Pharma and Doximity estimates. doximity >50% 20-50% 5-20% Year FY23 <5% # Mega Brands ~ 430 3000000 1000000 100000 ☐☐☐☐☐☐☐☐☐☐ ☐☐☐☐☐☐☐☐☐☐ 10000000 No Revenue in Trailing 12 Months Doximity Share ~4% 0000000 00000 000000 DOCS Investor Day June 6, 2023#42GROWTH VECTORS: +BRANDS & +MODULES # of Mega Brands We Work With 250 200 150 100 50 0 FY19 doximity Modules Per Mega Brand 1-2 3-4 FY21 5+ FY23 Avg Revenue Per Mega Brand¹ 1. Average revenue per "mega brand" is total revenue for all mega brands divided by the number of mega brands we work with for fiscal 2023. A mega brand is defined as brands with over $100m in US Sales. ~$4m ~$1.5m ~$500k DOCS Investor Day - June 6, 2023#43TOP 20 CUSTOMERS LEAD GROWTH Revenue from our Top 20 Customers FY17 FY18 1. See appendix for the definition of this metric. doximity FY19 Rev 3x+ in 3yrs First $10m+ Cust. FY20 FY21 FY22 11 $10m+ Custs. FY23 124% Top 20 Net Revenue Retention Rate¹ in FY23 DOCS Investor Day - June 6, 2023#44HIGH GROWTH, SUBS. BASED REVENUE 49% CAGR $86M FY19 $116M doximity FY20 Revenue $207M FY21 $344M FY22 $419M FY23 60-65% Subscription Revenue Visibility¹ 30-35% Launched/Contracted Renewal/Upsell ~5% New Customers Total 1. Subscription Revenue Visibility is defined as % of annual subscription-based revenue from deals signed ("contracted") as of the end of the quarter being reported. This chart is based on an average of our last 5 fiscal years. Subscription revenue accounts for -93% of our total revenue for all years since FY21. DOCS Investor Day - June 6, 2023#45ATTRACTIVE MARGIN PROFILE Non-GAAP Gross Profit & Margin¹ 50% CAGR $75M 88% FY19 $102M 87% doximity FY20 $176M 85% | FY21 $309M 90% FY22 $376M 90% FY23 1. See appendix for the definition and a reconciliation of this measure to its nearest GAAP equivalent. Adj. EBITDA & Margin¹ 107% CAGR $10M 11% FY19 $27M 23% FY20 $65M 31% FY21 $150M 44% FY22 $184M 44% FY23 87% CAGR $14M Free Cash Flow¹ FY19 $22M FY20 $78M FY21 $121M $173M FY22 FY23 DOCS Investor Day - June 6, 2023#46FINANCIAL OUTLOOK doximity DOCS Investor Day - June 6, 2023#47TARGET: $1B+ IN FY28 $419M FY23 doximity $503M FY24E Revenue ~20% CAGR $1B+ FY28E How We Get There Shift to digital: continued market growth and share gains Expansion opportunities: peer to peer and point of care Top customers lead growth: increase in number of 8-figure customers DOCS Investor Day - June 6, 2023#48KEY INPUTS ON PATH TO $1B+ doximity Business Line Contribution ~20% CAGR $419M FY23 $1B+ ~80% ~15% ~5% FY28E Current Business Peer to Peer & Point of Care New Business 2 Number of 8 Figure Customers 7 11 || FY21 FY22 FY23 +2-3 Avg per Year 20-25 FY28E DOCS Investor Day - June 6, 2023#49LONG-TERM OPERATING MODEL UPDATE 85-90% Non-GAAP Gross Margin¹ 1. See appendix for the definition and a reconciliation of this measure to its nearest GAAP equivalent. 2. We calculate "Rule of 65" as Revenue Growth + Adjusted EBITDA Margin. doximity 45%+ Adj. EBITDA Margin¹ Rule of 65 or Greater, Long Term² DOCS Investor Day June 6, 2023#50NEW REPURCHASE AUTHORIZATION doximity $200 Million Timing: 2 Years DOCS Investor Day y June 6, 2023#51Q&A doximity DOCS Investor Day - June 6, 2023#52THANK YOU! doximity DOCS Investor Day - June 6, 2023#53APPENDIX: NON-GAAP FINANCIAL MEASURES To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance: Non-GAAP gross profit and non-GAAP gross margin: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, change in fair value of contingent earn-out consideration liability, and expenses associated with acquisitions from non-GAAP gross profit and non-GAAP gross margin. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue. Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, change in fair value of contingent earn-out consideration liability, and other income, net. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue. Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs. We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results. Key Business Metrics Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates. The metric excludes the impact of the AMION acquisition, which closed on April 1, 2022, including customers of, and subscription revenue generated from, the AMION on-call scheduling and messaging application, and the impact of such acquisition was immaterial to the periods presented. Customers with trailing 12-month subscription revenue greater than $10 million: The number of customers with TTM subscription revenue greater than $10 million is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $10 million in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments. doximity DOCS Investor Day - June 6, 2023#54GAAP TO NON-GAAP RECONCILIATIONS NON-GAAP GROSS PROFIT & MARGIN GAAP Gross Profit Adjusted to exclude the following: Stock-based compensation Amortization of acquired intangibles Non-GAAP Gross Profit Revenue GAAP Gross Margin Non-GAAP Gross Margin doximity 2019 $74,806 194 $75,000 $85,695 87% 88% 2020 Year Ended March 31, 2021 (in thousands) $101,488 $175,701 173 600 87% 87% 2022 85% 85% $303,761 $101,661 $176,301 $308,740 $116,388 $206,897 $343,548 88% 90% 4,979 2023 $365,562 9,634 548 $375,744 $419,052 87% 90% DOCS Investor Day June 6, 2023 54#55GAAP TO NON-GAAP RECONCILIATIONS ADJUSTED EBITDA & MARGIN Net Income Adjustments: Acquisition and other related expenses Stock-based compensation Depreciation and amortization Revenue Change in fair value of contingent earn-out consideration liability Income tax expense (benefit) Other income, net Adjusted EBITDA Net Income Margin Adjusted EBITDA Margin doximity 2019 $7,833 2,343 551 2020 9% 11% Year Ended March 31, 2021 (in thousands) $50,210 $29,737 1,158 2,353 900 98 (6,223) (1,010) (1,351) $9,815 $26,574 $85,695 $116,388 26% 23% 496 7,252 3,702 2022 24% 31% $154,783 254 31,442 5,040 7,559 (4,466) $64,753 $150,272 $206,897 $343,548 (40,778) (469) 45% 44% 2023 $112,818 30 47,834 10,283 728 20,338 (8,048) $183,983 $419,052 27% 44% DOCS Investor Day - June 6, 2023 55#56GAAP TO NON-GAAP RECONCILIATIONS FREE CASH FLOW Net cash provided by operating activities Purchases of property and equipment Internal-use software development costs Free cash flow doximity 2019 $15,306 (114) (1,076) $14,116 2020 Year Ended March 31, $26,199 (285) (3,959) $21,955 2021 (in thousands) $82,973 (245) (4,365) $78,363 2022 2023 $126,575 $179,602 (1,912) (1,701) (3,785) (4,483) $120,878 $173,418 DOCS Investor Day - June 6, 2023 56